Vicapsys Life Sciences (Vicapsys Life Sciences) Ending Cash Position : $0.05 Mil (As of Sep. 2023)

View and export this data going back to . Start your Free Trial

What is Vicapsys Life Sciences Ending Cash Position?

Vicapsys Life Sciences's Ending Cash Position for the quarter that ended in Sep. 2023 was $0.05 Mil.

Vicapsys Life Sciences's quarterly Ending Cash Position increased from Mar. 2023 ($0.00 Mil) to Jun. 2023 ($0.23 Mil) but then declined from Jun. 2023 ($0.23 Mil) to Sep. 2023 ($0.05 Mil).

Vicapsys Life Sciences's annual Ending Cash Position increased from Dec. 2020 ($0.00 Mil) to Dec. 2021 ($0.22 Mil) but then declined from Dec. 2021 ($0.22 Mil) to Dec. 2022 ($0.01 Mil).

Vicapsys Life Sciences Ending Cash Position Historical Data

The historical data trend for Vicapsys Life Sciences's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vicapsys Life Sciences Ending Cash Position Chart

Vicapsys Life Sciences Annual Data

Trend

Dec08

Dec09

Dec19

Dec20

Dec21

Dec22

Ending Cash Position

Get a 7-Day Free Trial

0.12

0.26

0.22

0.01

Vicapsys Life Sciences Quarterly Data
	Jun10	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Ending Cash Position	Get a 7-Day Free Trial															0.03	0.01	-	0.23	0.05

Vicapsys Life Sciences Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Vicapsys Life Sciences's Ending Cash Position for the fiscal year that ended in Dec. 2022 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	0.217	+	-0.203
	=	0.01

Vicapsys Life Sciences's Ending Cash Position for the quarter that ended in Sep. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	0.161	+	-0.107
	=	0.05

Vicapsys Life Sciences Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Vicapsys Life Sciences's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Vicapsys Life Sciences (Vicapsys Life Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vicapsys Life Sciences Inc (OTCPK:VICP) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

7778 Mcginnis Ferry Road, Suite 270, Suwanee, GA, USA, 30024

Website

https://www.vicapsys.com

Vicapsys Life Sciences Inc is a biotech company that is engaged in commercializing implantable medical products that incorporate VICAPSYN, inducing a zone of immuno-protection around devices and cells implanted in the human body. The product name VICAPSYN is the company's line of proprietary product candidates that is applied to transplantation therapies and related stem-cell applications in the transplantation field.

Executives

Moore Bobby M Jr	10 percent owner	4125 S.B. MERRION ROAD, LAKELAND FL 33810
Robert Grammen	10 percent owner	9180 GALLENA COURT, NAPLES FL 34109
Michael Yurkowski	director	1505 ELM STREET, #1504, DALLAS TX 75201
William P. Esping	10 percent owner	2828 ROUTH STREET, SUITE 500, DALLAS TX 75201
Rodger Rees	director	C/O BONDS.COM GROUP, INC., 1515 SOUTH FEDERAL HIGHWAY, SUITE 212, BOCA RATON FL 33432
Mark Feldmesser	director	641 UNIVERSITY BLVE, JUPITER FL 33458
Federico Pier	director	1004 PLUM DRIVE, IRVING TX 75063
Ryan Seddon	director, 10 percent owner	8120 BELVEDERE ROAD, SUITE 4, WEST PALM BEACH FL 33411

Vicapsys Life Sciences (Vicapsys Life Sciences) Headlines

From GuruFocus

ViCapsys Life Sciences Appoints Federico Pier as Permanent Chief Executive Officer

By ACCESSWIRE ACCESSWIRE • 04-13-2022